

Supporting Information

Iridium/*f*-diaphos Catalyzed Asymmetric Hydrogenation of 2-Imidazolyl Aryl/Alkyl Ketones

Ze Wang, XiangHua Zhao, Shiliang Wang, An Huang, Yifan Wang, Jiaying He, Fei Ling,* and Weihui Zhong*

Key Laboratory for Green Pharmaceutical Technologies and Related Equipment of Ministry of Education,
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, People's
Republic of China

E-mail: weihuizhong@zjut.edu.cn


Table of Contents

I. General experimental information.....	2
II. General procedure for the preparation of ligands	3
III. General procedure for the asymmetric hydrogenation of 2-imidazolyl aryl ketones	7
IV. Gram scale reaction	15
V. References.....	16
VI. Copies of ¹ H and ¹³ C NMR spectra	17
VII. Copies of HPLC charts of chiral alcohols 2a-2v , 3a , 3h	60

I. General experimental information

Commercial reagents were used without further purification, and solvents were dried before using. Melting points were recorded with a micro melting point apparatus and uncorrected. The ¹H NMR spectra were recorded at 400 or 600 MHz. The ¹³C NMR spectra were recorded at 100 MHz or 150 MHz. Chemical shifts were expressed in parts per million (δ) downfield from the internal standard tetramethylsilane, and were reported as s (singlet), d (doublet), t (triplet), dd (doublet of doublet), m (multiplet), br s (broad singlet), etc. The coupling constants J were given in Hz. HRMS spectra were recorded on an Agilent 1200HPLC-6210TOFMS using ESI as ion source. The conversion of starting materials was monitored by thin layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm). Optical rotations were determined using an AUTOPOL V polarimeter. HPLC analyses were performed using Agilent 1100 equipped with IA-H, IC-H, OD-H and AD-H.

II. General procedure for the preparation of ligands



After being flushed with Ar, A solution of (R_c, S_{FC})-**A** (1 mmol), (R, R)-1,2-diamine-**B** (1.5 mmol) in dry MeOH (1 mL) was stirred at reflux overnight. Upon completion, the reaction mixture was cooled to room temperature. Then, the resulting mixture was diluted with DCM (20 mL), and washed with water (10 mL) and brine (10 mL). The organic layer was dried over anhydrous Na_2SO_4 , and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether/ethyl acetate (10:1) as the eluent to give **L1** (90.9 mg, 78%). **L2-L12** were obtained in a similar manner.

The *f*-diaphos ligands **L1**, **L4-L6**, **L8** and **L12** have been reported in our previous work.^{1,2}
N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L1)

Orange solid, 65% yield, 431.7 mg, mp 153-154 °C, $[\alpha]^{20}_{\text{D}} = -129.1$ (c = 0.5, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, $J = 7.6$ Hz, 2H), 7.52 (s, 2H), 7.42 (s, 3H), 7.29 (d, $J = 7.6$ Hz, 2H), 7.21 (s, 1H), 7.10 (s, 4H), 5.91 (s, 1H), 4.55 (s, 1H), 4.39 (s, 1H), 4.10-4.05 (m, 6H), 3.73 (s, 1H), 2.47 (s, 3H), 2.15 (s, 2H), 1.97-1.88 (m, 2H), 1.50 (s, 2H), 1.39 (d, $J = 4.0$ Hz, 3H), 1.11-0.99 (m, 2H), 0.90-0.83 (m, 1H), -0.26 to -0.28 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 142.7, 139.9, 139.8, 137.2, 136.7, 136.6, 135.0, 134.8, 132.8, 132.6, 129.4, 129.1, 128.32, 128.27, 128.2, 128.1, 127.5, 98.2, 74.3, 74.2, 71.14, 71.10, 69.7, 69.5, 69.2, 57.7, 56.9, 32.1, 29.8, 24.8, 23.9, 21.5, 20.0. ^{31}P NMR (162 MHz, CDCl_3) δ -24.85. HRMS (ESI) calcd for $\text{C}_{37}\text{H}_{42}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 665.2049, found: 665.2053.

N-((1*S*,2*S*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L2)

Orange solid, 61% yield, 405.2 mg, mp 141-142 °C, $[\alpha]^{20}_{\text{D}} = -72.5$ (c = 0.5, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, $J = 8.0$ Hz, 2H), 7.64 (s, 2H), 7.42 (s, 3H), 7.31-7.30 (m, 7H), 5.15 (s, 1H), 4.46 (s, 2H), 4.07 (s, 2H), 3.96 (s, 5H), 2.47 (s, 3H), 2.41 (s, 1H), 1.99 (d, $J = 8.4$ Hz, 1H), 1.87-1.84 (m, 2H), 1.46-1.45 (m, 3H), 1.38-1.24 (m, 3H), 1.00-0.92 (m, 1H), 0.79-0.67 (m, 2H), 0.55-0.52 (m, 1H). ^{13}C NMR

(100 MHz, CDCl₃) δ 142.9, 140.24, 140.16, 137.84, 137.76, 137.6, 135.3, 135.1, 132.8, 132.6, 129.5, 129.2, 128.4, 128.3, 128.14, 128.11, 128.06, 127.3, 100.0, 74.0, 70.94, 70.90, 69.9, 69.7, 68.6, 68.5, 56.8, 47.5, 47.4, 31.9, 31.7, 24.8, 24.0, 23.8, 21.6. ³¹P NMR (162 MHz, CDCl₃) δ -24.83. HRMS (ESI) calcd for C₃₇H₄₂FeN₂O₂PS [M+H]⁺: 665.2049, found: 665.2044.

N-((1*R*,2*R*)-2-(((*S*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L3)

Orange solid, 64% yield, 425.1 mg, mp 146-147 °C, [α]²⁰_D = +85.8 (c = 0.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 2H), 7.52-7.42 (m, 5H), 7.30-7.10 (m, 7H), 5.92 (s, 1H), 4.55 (s, 1H), 4.39 (s, 1H), 4.10 (s, 6H), 3.73 (s, 1H), 2.48 (s, 3H), 2.15 (s, 2H), 1.94-1.87 (m, 2H), 1.49-1.39 (m, 6H), 1.06-0.86 (m, 3H), -0.29 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 142.8, 137.2, 136.6, 135.0, 134.8, 132.8, 132.6, 129.4, 129.2, 128.3, 127.5, 72.5, 71.1, 69.7, 69.2, 57.7, 56.9, 32.1, 29.8, 24.8, 23.9, 21.6, 20.0. ³¹P NMR (162 MHz, CDCl₃) δ -26.90. HRMS (ESI) calcd for C₃₇H₄₂FeN₂O₂PS [M+H]⁺: 665.2049, found: 665.2059.

N-((1*S*,2*S*)-2-(((*S*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L4)

Orange solid, 65% yield, 431.7 mg, mp 146-147 °C, [α]²⁰_D = +60.1 (c = 0.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 7.6 Hz, 2H), 7.57 (s, 2H), 7.47 (s, 3H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.25 (d, *J* = 4.0 Hz, 1H), 7.15 (s, 4H), 5.97 (s, 1H), 4.60 (s, 1H), 4.44 (s, 1H), 4.15 (s, 5H), 4.09 (d, *J* = 7.2 Hz, 1H), 3.78 (s, 1H), 2.53 (s, 3H), 2.20 (s, 2H), 2.01-1.91 (m, 2H), 1.54 (t, *J* = 11.6 Hz, 2H), 1.44 (s, 3H), 1.15-1.06 (m, 2H), 0.94-0.87 (m, 1H), -0.24 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 142.8, 139.8, 137.1, 136.6, 135.0, 134.8, 132.8, 132.6, 129.4, 129.2, 128.4, 128.2, 128.1, 127.5, 74.2, 71.1, 69.7, 69.3, 57.7, 56.9, 32.1, 29.7, 24.7, 23.9, 21.6, 20.0. ³¹P NMR (162 MHz, CDCl₃) δ -25.03. HRMS (ESI) calcd for C₃₇H₄₂FeN₂O₂PS [M+H]⁺: 665.2049, found: 665.2056.

N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L5)

Orange solid, 60% yield, 415.3 mg, mp 162-163 °C, [α]²⁰_D = -124.8 (c = 0.5, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (s, 2H), 7.42 (s, 3H), 7.19 (s, 1H), 7.08 (s, 4H), 6.96 (s, 2H), 5.96 (s, 1H), 4.53 (s, 1H), 4.38 (s, 1H), 4.10 (s, 6H), 3.74 (s, 1H), 2.63 (s, 6H), 2.36 (s, 3H), 2.14-2.09 (m, 2H), 1.94-1.91 (m, 1H), 1.79 (s, 1H), 1.47-1.45 (m, 5H), 1.07-0.90 (m, 2H), 0.86-0.79 (m, 1H), -0.40 (d, *J* = 9.2 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 141.5, 140.1, 140.0, 139.1, 136.5, 136.4, 135.1, 134.9, 134.2, 132.7, 132.5, 131.8, 129.2, 128.41, 128.35, 128.2, 128.1, 98.0, 74.12, 74.07, 71.1, 69.7, 69.4, 69.2, 57.7, 57.0, 46.2,

32.0, 29.8, 24.9, 23.9, 23.1, 20.9, 19.9. ^{31}P NMR (162 MHz, CDCl_3) δ -25.07. HRMS (ESI) calcd for $\text{C}_{39}\text{H}_{46}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 693.2362, found: 693.2355.

N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-triisopropylbenzenesulfonamide (L6)

Orange solid, 48% yield, 372.6 mg, mp 148-149 °C, $[\alpha]^{20}_{\text{D}} = -56.1$ ($c = 0.5$, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.54 (d, $J = 7.2$ Hz, 2H), 7.41 (s, 3H), 7.19 (s, 2H), 7.14 (s, 3H), 7.03 (d, $J = 6.4$ Hz, 2H), 5.98 (s, 1H), 4.54 (s, 1H), 4.32 (s, 1H), 4.11 (t, $J = 7.2$ Hz, 1H), 4.08 (s, 5H), 3.70 (s, 1H), 3.00-2.93 (m, 1H), 2.19-2.04 (m, 4H), 1.56-1.43 (m, 5H), 1.34-1.31 (m, 7H), 1.27 (d, $J = 6.8$ Hz, 6H), 1.21 (d, $J = 6.4$ Hz, 6H), 1.10-1.00 (m, 2H), 0.92-0.86 (m, 2H), -0.13 (d, $J = 12.4$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 152.1, 150.3, 135.2, 135.0, 132.8, 132.6, 129.2, 128.3, 128.2, 128.1, 123.6, 97.5, 97.3, 71.2, 69.7, 69.1, 57.4, 57.3, 46.6, 34.1, 32.0, 29.9, 29.7, 25.2, 25.1, 23.9, 23.7, 23.6, 19.8. ^{31}P NMR (162 MHz, CDCl_3) δ -25.02. HRMS (ESI) calcd for $\text{C}_{45}\text{H}_{58}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 777.3301, found: 777.3310.

N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-3,5-bis(trifluoromethyl)benzenesulfonamide (L7)

Orange solid, 52% yield, 408.8 mg, mp 106-108 °C, $[\alpha]^{20}_{\text{D}} = -138.6$ ($c = 0.6$, MeOH). ^1H NMR (400 MHz, CDCl_3) δ 8.33 (s, 2H), 8.11 (s, 1H), 7.56-7.52 (m, 2H), 7.43 (s, 3H), 7.26-7.24 (m, 1H), 7.21-7.19 (m, 4H), 4.51 (s, 1H), 4.38 (s, 1H), 4.13-4.09 (m, 6H), 3.76 (s, 1H), 2.17 (t, $J = 8.4$ Hz, 1H), 2.04 (d, $J = 6.8$ Hz, 3H), 1.55 (d, $J = 11.2$ Hz, 2H), 1.41 (d, $J = 6.8$ Hz, 3H), 1.06-0.94 (m, 3H), -0.03 (d, $J = 12.4$ Hz, 1H). ^{13}C NMR (150 MHz, CDCl_3) δ 144.0, 139.9, 139.8, 136.4, 136.3, 135.1, 134.9, 132.9, 132.7, 132.6 (q, $^2J_{\text{C}-\text{F}} = 51.2$ Hz), 129.2, 128.5, 128.4 (q, $^3J_{\text{C}-\text{F}} = 9.6$ Hz), 128.2 (q, $^3J_{\text{C}-\text{F}} = 11.6$ Hz), 127.4, 125.8, 122.5 (q, $^1J_{\text{C}-\text{F}} = 257.9$ Hz), 97.5, 97.2, 74.3, 71.33, 71.29, 69.7, 69.5, 58.3, 57.1, 47.0, 46.9, 31.7, 30.0, 24.8, 23.8, 20.1. ^{19}F NMR (376 MHz, CDCl_3) δ -63.03. ^{31}P NMR (162 MHz, CDCl_3) δ -25.42. HRMS (ESI) calcd for $\text{C}_{38}\text{H}_{38}\text{F}_6\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 787.1640, found: 787.1648.

N-((1*R*,2*R*)-2-(((*R*)-1-(2-(bis(3,5-dimethylphenyl)phosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L8)

Orange solid, 56% yield, 442.5 mg, mp 100-101 °C, $[\alpha]^{20}_{\text{D}} = -141.2$ ($c = 0.5$, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.57 (s, 2H), 7.43 (s, 6H), 7.33-7.28 (m, 2H), 7.12 (d, $J = 6.8$ Hz, 1H), 7.05 (t, $J = 7.2$ Hz, 2H), 6.94 (t, $J = 7.2$ Hz, 1H), 6.82 (t, $J = 7.2$ Hz, 3H), 6.75 (s, 2H), 6.67 (d, $J = 7.2$ Hz, 2H), 6.46 (d, $J = 6.8$ Hz, 2H), 4.52 (s, 1H), 4.39 (s, 1H), 4.03 (s, 6H), 3.93 (d, $J = 8.4$ Hz, 1H), 3.77 (s, 1H), 3.70-3.63 (m, 2H), 2.44 (s, 6H), 2.26 (s, 3H), 1.72 (s, 1H), 1.37 (d, $J = 3.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 141.4, 140.9, 140.8, 139.0, 138.4, 137.8, 137.4, 135.5, 135.3, 134.6, 132.6, 132.4, 131.3, 129.1, 128.5, 128.3,

128.14, 128.09, 128.0, 127.6, 127.5, 127.2, 126.9, 98.6, 74.0, 73.9, 71.4, 70.0, 69.7, 69.5, 65.0, 63.4, 47.5, 22.8, 20.8, 19.9. ^{31}P NMR (162 MHz, CDCl_3) δ -24.43. HRMS (ESI) calcd for $\text{C}_{47}\text{H}_{48}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 791.2518, found: 791.2510.

N-((1R,2R)-2-(((R)-1-(2-(dicyclohexylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L9)

Orange solid, 62% yield, 446.5 mg, mp 216-217 °C, $[\alpha]^{25}_{\text{D}} = -439.6$ ($c = 0.4$, MeOH). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.53 (s, 1H), 7.82 (s, 2H), 7.64-7.60 (m, 2H), 7.47-7.44 (m, 5H), 7.04-7.03 (m, 4H), 6.70 (s, 1H), 5.49 (s, 1H), 4.79 (s, 1H), 4.50 (s, 1H), 4.15 (s, 5H), 3.71 (s, 1H), 1.72 (d, $J = 6.4$ Hz, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 184.0, 179.8, 167.8, 161.3, 141.6, 139.1, 136.7, 135.1, 134.9, 132.8, 132.6, 131.7 (q, $^{2}\text{J}_{\text{C-F}} = 32.8$ Hz), 129.6, 128.6, 128.3, 127.6, 123.6 (q, $^{1}\text{J}_{\text{C-F}} = 271.2$ Hz), 117.8, 114.6, 94.3, 94.0, 75.7, 72.2, 70.2, 69.7, 69.0, 55.3, 49.0, 22.1. ^{19}F NMR (376 MHz, CDCl_3) δ -57.10. ^{31}P NMR (162 MHz, CDCl_3) δ -21.36. HRMS (ESI) calcd for $\text{C}_{36}\text{H}_{28}\text{F}_6\text{FeN}_2\text{O}_2\text{P} [\text{M}+\text{H}]^+$: 721.1137, found: 721.1149.

N-((1R,2R)-2-(((R)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)-1,2-diphenylethyl)-2,4,6-trimethylbenzenesulfonamide (L10)

Orange solid, 50% yield, 374.2 mg, mp 90-91 °C, $[\alpha]^{20}_{\text{D}} = -79.0$ ($c = 0.5$, CHCl_3). ^1H NMR (400 MHz, CDCl_3) δ 7.19 (s, 1H), 7.17 (s, 1H), 7.06 (s, 1H), 6.93 (s, 2H), 6.89 (s, 1H), 6.79 (s, 1H), 6.77 (s, 1H), 6.01 (s, 1H), 4.51 (s, 1H), 4.36 (s, 1H), 4.10-4.06 (m, 6H), 3.76 (s, 1H), 2.65 (s, 6H), 2.36 (s, 6H), 2.31 (s, 3H), 2.15 (s, 6H), 2.09-2.06 (m, 2H), 1.95 (s, 1H), 1.86-1.83 (m, 1H), 1.48-1.42 (m, 4H), 1.34-1.31 (m, 1H), 1.03-0.97 (m, 2H), 0.93-0.87 (m, 2H), -0.34 (d, $J = 9.6$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 141.5, 139.5, 139.4, 138.9, 137.93, 137.86, 137.5, 137.4, 136.3, 136.2, 134.7, 132.8, 132.6, 131.8, 130.9, 130.7, 130.5, 130.0, 75.0, 74.9, 71.1, 69.6, 69.3, 69.0, 57.8, 57.3, 31.3, 29.8, 29.7, 26.9, 25.0, 23.9, 22.9, 21.4, 21.1, 20.9, 20.4. ^{31}P NMR (162 MHz, CDCl_3) δ -25.06. HRMS (ESI) calcd for $\text{C}_{43}\text{H}_{54}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 749.2988, found: 749.3001.

(R)-3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-((1-(2-

(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclobut-3-ene-1,2-dione (L11)


Orange solid, 47% yield, 331.0 mg, mp 86-87 °C, $[\alpha]^{25}_{\text{D}} = -89.4$ ($c = 0.5$, MeOH). ^1H NMR (400 MHz, CDCl_3) δ 6.87 (s, 2H), 6.11 (s, 1H), 4.42 (s, 1H), 4.35 (s, 1H), 4.20 (s, 5H), 4.15 (s, 1H), 3.97 (s, 1H), 2.63 (s, 6H), 2.35-2.29 (m, 4H), 2.26 (s, 3H), 2.18 (d, $J = 9.6$ Hz, 2H), 2.12-2.07 (m, 1H), 1.96-1.87 (m, 2H), 1.80-1.78 (m, 2H), 1.72-1.65 (m, 4H), 1.56-1.53 (m, 2H), 1.49 (d, $J = 6.4$ Hz, 3H), 1.44-1.30 (m, 4H), 1.19-1.10 (m, 8H), 0.92-0.75 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 141.5, 138.9, 134.0, 131.8,

70.7, 69.4, 68.7, 67.3, 58.3, 57.5, 37.5, 37.3, 35.4, 35.3, 33.7, 33.4, 32.3, 31.7, 31.4, 31.3, 31.2, 31.0, 29.7, 29.5, 28.4, 28.3, 27.73, 27.68, 27.3, 27.2, 27.0, 26.9, 26.4, 25.2, 24.3, 23.1, 21.0, 20.9. ^{31}P NMR (162 MHz, CDCl_3) δ -17.85. HRMS (ESI) calcd for $\text{C}_{39}\text{H}_{58}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 705.3301, found: 705.3296.

N-((1*S*,2*S*)-2-(((*S*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L12)

Orange solid, 60% yield, 415.3 mg, mp 159-160 °C, $[\alpha]^{20}_{\text{D}} = +67.9$ ($c = 0.63$, EtOH). ^1H NMR (400 MHz, CDCl_3) δ 7.55-7.51 (m, 2H), 7.41 (d, $J = 4.4$ Hz, 3H), 7.19 (t, $J = 4.4$ Hz, 1H), 7.07 (s, 4H), 6.96 (s, 2H), 5.97 (s, 1H), 4.53 (s, 1H), 4.38 (s, 1H), 4.10 (s, 6H), 3.74 (s, 1H), 2.63 (s, 6H), 2.35 (s, 3H), 2.13 (d, $J = 9.6$ Hz, 2H), 1.93 (d, $J = 12.4$ Hz, 1H), 1.79 (s, 1H), 1.51-1.44 (m, 5H), 1.07-1.01 (m, 2H), 0.86-0.79 (m, 1H), -0.40 (d, $J = 10.4$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 141.5, 140.1, 140.0, 139.1, 136.5, 136.4, 135.1, 134.9, 134.2, 132.7, 132.5, 131.8, 129.2, 128.4, 128.3, 128.2, 128.1, 97.7, 74.1, 71.12, 71.09, 69.7, 69.4, 69.2, 57.7, 57.0, 46.2, 32.0, 29.8, 24.9, 24.0, 23.1, 21.0, 19.9. ^{31}P NMR (162 MHz, CDCl_3) δ -24.91. HRMS (ESI) calcd for $\text{C}_{39}\text{H}_{46}\text{FeN}_2\text{O}_2\text{PS} [\text{M}+\text{H}]^+$: 693.2362, found: 693.2357.

III. General procedure for the asymmetric hydrogenation of 2-imidazolyl aryl ketones



Condition A:

Under argon atmosphere, $[\text{Ir}(\text{COD})\text{Cl}]_2$ (1.7 mg, 0.0025 mmol), **L5** (3.8 mg, 0.0055 mmol), and anhydrous $^i\text{PrOH}$ (1 mL) were added to an oven-dried vial (10 mL) and then stirred at 30 °C for 1.5 h to give a clear yellow solution. The mixture was concentrated to dryness, then 1 mL of dried Toluene was added to the crude **Ir-L5** complex. An aliquot of the catalyst solution (0.2 mL, 0.0005 mmol) was transferred into a 10 mL hydrogenation vessel, and then ketones (1.0 mmol), HCO_2Na (3.4 mg, 0.05 mmol) and anhydrous Toluene (2 mL) were added. The vial was placed in an alloy plate which was then placed into the autoclave. And the autoclave was purged five times with hydrogen, then pressurized to 45 atm of H_2 and stirred at 70 °C for 12 h. Upon completion, the reaction mixture was cooled to room temperature. After the hydrogen pressure was slowly released, the solvent was removed, and the mixture

was purified by passing through a short column of silica gel to afford **2a-2r**. The *ee* values of all compounds were determined by HPLC with a chiral column.

Condition B:

Under argon atmosphere, $[\text{Ir}(\text{COD})\text{Cl}]_2$ (1.7 mg, 0.0025 mmol), **L1** (3.7 mg, 0.0055 mmol), and anhydrous $^i\text{PrOH}$ (1 mL) were added to an oven-dried vial (10 mL) and then stirred at 30 °C for 1.5 h to give a clear yellow solution. The mixture was concentrated to dryness, then 1 mL of dried Toluene was added to the crude Ir-**L1** complex. An aliquot of the catalyst solution (0.2 mL, 0.0005 mmol) was transferred into a 10 mL hydrogenation vessel, and then ketones (1.0 mmol), $^t\text{BuOLi}$ (4 mg, 0.05 mmol) and anhydrous $^i\text{PrOH}$ (2 mL) were added. The vial was placed in an alloy plate which was then placed into the autoclave. And the autoclave was purged five times with hydrogen, then pressurized to 30 atm of H_2 and stirred at 40 °C for 12 h. Upon completion, the reaction mixture was cooled to room temperature. After the hydrogen pressure was slowly released, the solvent was removed, and the mixture was purified by passing through a short column of silica gel to afford **2s-2v**. The *ee* values of all compounds were determined by HPLC with a chiral column.

Condition C:

Under argon atmosphere, $[\text{Ir}(\text{COD})\text{Cl}]_2$ (1.7 mg, 0.0025 mmol), **L12** (3.8 mg, 0.0055 mmol), and anhydrous $^i\text{PrOH}$ (1 mL) were added to an oven-dried vial (10 mL) and then stirred at 30 °C for 1.5 h to give a clear yellow solution. The mixture was concentrated to dryness, then 1 mL of dried Toluene was added to the crude Ir-**L12** complex. An aliquot of the catalyst solution (0.2 mL, 0.0005 mmol) was transferred into a 10 mL hydrogenation vessel, and then ketones (1.0 mmol), HCO_2Na (3.4 mg, 0.05 mmol) and anhydrous Toluene (2 mL) were added. The vial was placed in an alloy plate which was then placed into the autoclave. And the autoclave was purged five times with hydrogen, then pressurized to 45 atm of H_2 and stirred at 70 °C for 12 h. Upon completion, the reaction mixture was cooled to room temperature. After the hydrogen pressure was slowly released, the solvent was removed, and the mixture was purified by passing through a short column of silica gel to afford **3a** and **3h**. The *ee* values of all compounds were determined by HPLC with a chiral column.

(R)-phenyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2a)

White solid, 99% yield, 131.7 mg, mp 211-212 °C, $[\alpha]^{25}_{\text{D}} = +73.9$ ($c = 0.66$, MeOH). The *ee* was determined by HPLC on Chiraldak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 9.83$ min (minor), $t_{\text{R}}(R) = 13.98$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.41 (d, $J = 7.2$ Hz, 3H), 7.35-7.29 (m, 3H), 6.94 (s, 1H), 6.17 (s, 1H), 3.47 (s, 3H), 2.38 (s,

3H), 2.37 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.5, 140.2, 139.4, 134.8, 132.0, 130.9, 128.5, 127.7, 126.4, 119.1, 109.4, 69.6, 30.2, 20.5, 20.2. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 267.1492, found: 267.1501.

(R)-(5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2b)

White solid, 99% yield, 124.8 mg, mp 216-217 °C, $[\alpha]^{25}_{\text{D}} = -36.2$ ($c = 0.9$, MeOH); lit. ^[3] mp 210-211 °C, $[\alpha]^{21}_{\text{D}} = -82.7$ ($c = 1.0$, water, 99% *ee*). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 9.10$ min (minor), $t_{\text{R}}(R) = 19.44$ min (major). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 12.16 (br, 1H), 7.51 (d, $J = 7.6$ Hz, 2H), 7.36 (t, $J = 7.6$ Hz, 2H), 7.29-7.26 (m, 3H), 6.50 (s, 1H), 5.91 (s, 1H), 2.30 (s, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 156.5, 143.1, 130.1, 128.5, 127.7, 126.9, 70.4, 20.4. HRMS (ESI) calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 253.1335, found: 253.1342.

(R)-(1-benzyl-5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2c)

White solid, 95% yield, 162.5 mg, mp 216-217 °C, $[\alpha]^{25}_{\text{D}} = +42.0$ ($c = 0.35$, MeOH). The *ee* was determined by HPLC on Chiralpak IA-H column, hexane: isopropanol = 95:5; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 25.72$ min (minor), $t_{\text{R}}(R) = 30.61$ min (major). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.42 (t, $J = 7.6$ Hz, 3H), 7.32 (t, $J = 7.6$ Hz, 2H), 7.27-7.23 (m, 4H), 7.01 (d, $J = 4.8$ Hz, 3H), 6.61 (d, $J = 4.8$ Hz, 1H), 6.13 (d, $J = 4.8$ Hz, 1H), 5.47 (s, 2H), 2.29 (s, 3H), 2.23 (s, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 155.0, 142.0, 137.4, 134.5, 131.4, 130.5, 128.8, 128.5, 127.6, 127.0, 126.5, 119.7, 111.2, 69.4, 47.2, 20.6, 20.3. HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 343.1805, found: 343.1816.

(R)-(5,6-dimethyl-1-phenyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2d)

White solid, 90% yield, 147.7 mg, mp 145-146 °C, $[\alpha]^{25}_{\text{D}} = +20.9$ ($c = 0.5$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 8.79$ min (minor), $t_{\text{R}}(R) = 10.04$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.51-7.44 (m, 4H), 7.22-7.16 (m, 5H), 7.09 (s, 2H), 6.87 (s, 1H), 5.90 (s, 1H), 4.75 (br, 1H), 2.41 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 155.0, 132.5, 131.6, 129.6, 128.9, 128.3, 127.9, 127.7, 119.6, 110.4, 69.7, 20.4, 20.2. HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 329.1648, found: 329.1655.

(R)-(1-isopropyl-5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2e)

White solid, 99% yield, 145.6 mg, mp 201-202 °C, $[\alpha]^{25}_{\text{D}} = +66.4$ ($c = 0.7$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 85:15; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(R) = 4.15$ min (major), $t_{\text{R}}(S) = 4.96$ min (minor). ^1H NMR (400 MHz,

CDCl_3) δ 7.45 (s, 1H), 7.38 (d, $J = 7.2$ Hz, 2H), 7.33-7.26 (m, 4H), 6.21 (s, 1H), 2.40 (s, 3H), 2.35 (s, 3H), 1.38 (d, $J = 6.8$ Hz, 3H), 1.22 (d, $J = 6.8$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.3, 140.8, 140.6, 132.3, 131.4, 130.7, 128.3, 127.5, 126.2, 119.7, 112.6, 69.7, 48.1, 20.7, 20.6, 20.2, 20.1. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{23}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 295.1805, found: 295.1800.

(R)-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2f)

White solid, 99% yield, 117.9 mg, mp 178-179 °C, $[\alpha]^{25}_{\text{D}} = +107.8$ ($c = 0.34$, MeOH); lit. [4] $[\alpha]_{\text{D}} = +119.1$ ($c = 1.0$, MeOH, 99% ee). The ee was determined by HPLC on Chiraldak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 9.64$ min (minor), $t_{\text{R}}(R) = 11.76$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.72 (t, $J = 4.0$ Hz, 1H), 7.43 (d, $J = 7.2$ Hz, 2H), 7.37-7.30 (m, 3H), 7.28-7.24 (m, 2H), 7.17 (t, $J = 4.0$ Hz, 1H), 6.23 (s, 1H), 5.58 (br, 1H), 3.51 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 155.5, 140.9, 140.0, 136.2, 128.5, 127.7, 126.2, 122.8, 122.1, 119.1, 109.2, 69.7, 30.3. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 239.1179, found: 239.1188.

(R)-(5,6-difluoro-1-methyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2g)

White solid, 95% yield, 130.2 mg, mp 203-204 °C, $[\alpha]^{25}_{\text{D}} = +108.1$ ($c = 0.76$, MeOH). The ee was determined by HPLC on Chiraldak AD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 8.00$ min (minor), $t_{\text{R}}(R) = 13.44$ min (major). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.72-7.65 (m, 2H), 7.43 (d, $J = 7.6$ Hz, 2H), 7.37 (t, $J = 7.6$ Hz, 2H), 7.28 (t, $J = 7.2$ Hz, 1H), 6.60 (s, 1H), 6.11 (s, 1H), 3.72 (s, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 157.7, 147.5 (dd, $^1J_{\text{C-F}} = 237.5$ Hz, $^2J_{\text{C-F}} = 15.4$ Hz), 147.0 (dd, $^1J_{\text{C-F}} = 235.4$ Hz, $^2J_{\text{C-F}} = 14.9$ Hz), 141.4, 137.2 (d, $^3J_{\text{C-F}} = 10.7$ Hz), 132.3 (d, $^3J_{\text{C-F}} = 11.2$ Hz), 128.6, 127.8, 126.6, 106.8 (d, $^2J_{\text{C-F}} = 19.2$ Hz), 99.0 (d, $^2J_{\text{C-F}} = 22.8$ Hz), 69.2, 31.1. HRMS (ESI) calcd for $\text{C}_{15}\text{H}_{13}\text{F}_2\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 275.0990, found: 275.0999.

(R)-(1-methyl-1*H*-imidazol-2-yl)(phenyl)methanol (2h)

White solid, 99% yield, 93.1 mg, mp 140-141 °C, $[\alpha]^{25}_{\text{D}} = +66.7$ ($c = 0.36$, MeOH). The ee was determined by HPLC on Chiraldak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 6.49$ min (minor), $t_{\text{R}}(R) = 12.50$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.38-7.32 (m, 4H), 7.31-7.26 (m, 1H), 6.84 (s, 1H), 6.73 (m, 1H), 6.55 (s, 1H), 5.99 (s, 1H), 3.42 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 149.3, 141.0, 128.3, 127.3, 126.1, 126.0, 122.1, 68.8, 33.2. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 189.1022, found: 189.1030.

(R)-*p*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2i)

White solid, 99% yield, 138.7 mg, mp 187-188 °C, $[\alpha]^{25}_{\text{D}} = +82.4$ ($c = 0.6$, MeOH). The ee was determined by HPLC on Chiraldak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min;

UV detection at 254 nm; $t_R(S) = 8.00$ min (minor), $t_R(R) = 10.57$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.32 (s, 1H), 7.27 (d, $J = 8.0$ Hz, 2H), 7.10 (d, $J = 8.0$ Hz, 2H), 6.89 (s, 1H), 6.15 (s, 1H), 3.46 (s, 3H), 2.36 (s, 3H), 2.344 (s, 3H), 2.337 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.9, 139.5, 137.5, 137.1, 134.7, 131.7, 130.7, 129.1, 126.2, 119.1, 109.4, 69.5, 30.3, 21.2, 20.6, 20.2. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{21}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 281.1648, found: 281.1655.

(R)-(4-fluorophenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2j)

White solid, 99% yield, 140.6 mg, mp 188-189 °C, $[\alpha]^{25}_{\text{D}} = +67.8$ ($c = 0.92$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_R(S) = 7.79$ min (minor), $t_R(R) = 10.32$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.35-7.31 (m, 3H), 6.99-6.92 (m, 3H), 6.13 (s, 1H), 3.48 (s, 3H), 2.38 (s, 3H), 2.33 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.2 (d, $^1J_{\text{C}-\text{F}} = 244.4$ Hz), 154.4, 139.4, 136.2, 134.7, 132.1, 131.0, 127.9 (d, $^3J_{\text{C}-\text{F}} = 8.1$ Hz), 119.0, 115.2 (d, $^2J_{\text{C}-\text{F}} = 21.4$ Hz), 109.4, 68.9, 30.2, 20.5, 20.1. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{18}\text{FN}_2\text{O} [\text{M}+\text{H}]^+$: 285.1398, found: 285.1407.

(R)-(4-chlorophenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2k)

White solid, 95% yield, 142.6 mg, mp 191-192 °C, $[\alpha]^{25}_{\text{D}} = +43.0$ ($c = 0.86$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 80:20; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_R(S) = 5.48$ min (minor), $t_R(R) = 6.47$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.30-7.24 (m, 5H), 6.93 (s, 1H), 6.10 (s, 1H), 3.48 (s, 3H), 2.38 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.1, 139.3, 138.9, 134.7, 133.3, 132.2, 131.1, 128.5, 127.5, 119.0, 109.5, 68.9, 30.3, 20.5, 20.1. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{18}\text{ClN}_2\text{O} [\text{M}+\text{H}]^+$: 301.1102, found: 301.1111.

(R)-(4-(trifluoromethyl)phenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2l)

White solid, 92% yield, 153.7 mg, mp 222-223 °C, $[\alpha]^{25}_{\text{D}} = +67.1$ ($c = 0.8$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_R(S) = 7.10$ min (minor), $t_R(R) = 9.31$ min (major). ^1H NMR (600 MHz, CDCl_3) δ 7.58 (d, $J = 8.4$ Hz, 2H), 7.52 (d, $J = 8.4$ Hz, 2H), 7.42 (s, 1H), 6.98 (s, 1H), 6.21 (s, 1H), 3.51 (s, 3H), 2.37 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 153.5, 144.0, 138.6, 134.5, 132.7, 131.7, 130.1, 126.6, 125.4 (q, $^4J_{\text{C}-\text{F}} = 2.6$ Hz), 124.0 (q, $^1J_{\text{C}-\text{F}} = 180.6$ Hz), 118.8, 109.6, 68.9, 30.4, 20.5, 20.2. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{18}\text{F}_3\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 335.1366, found: 335.1374.

(R)-*m*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2m)

White solid, 99% yield, 138.7 mg, mp 189-190 °C, $[\alpha]^{25}_{\text{D}} = +104.8$ ($c = 0.6$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min;

UV detection at 254 nm; $t_R(S) = 7.45$ min (minor), $t_R(R) = 10.83$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.42 (d, $J = 5.2$ Hz, 1H), 7.22-7.18 (m, 3H), 7.10 (d, $J = 6.8$ Hz, 1H), 6.93 (s, 1H), 6.13 (s, 1H), 3.47 (s, 3H), 2.38 (s, 3H), 2.37 (s, 3H), 2.32 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.7, 140.2, 139.5, 138.2, 134.8, 131.8, 130.8, 128.4, 128.3, 127.0, 123.4, 119.2, 109.4, 69.7, 30.2, 21.4, 20.5, 20.2. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{21}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 281.1648, found: 281.1655.

(R)-*o*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2n)

White solid, 97% yield, 135.9 mg, mp 193-194 °C, $[\alpha]^{25}_{\text{D}} = +71.9$ ($c = 0.8$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_R(S) = 9.09$ min (minor), $t_R(R) = 10.18$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.26 (s, 1H), 7.22-7.21 (m, 3H), 7.12-7.08 (m, 1H), 6.92 (s, 1H), 6.24 (s, 1H), 6.15 (br, 1H), 3.37 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.5, 139.3, 138.2, 136.6, 134.4, 131.7, 130.7, 128.1, 127.0, 126.1, 119.1, 109.3, 67.5, 30.0, 20.6, 20.2, 19.4. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{21}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 281.1648, found: 281.1659.

(R)-(3,5-dimethylphenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2o)

White solid, 99% yield, 145.6 mg, mp 197-198 °C, $[\alpha]^{25}_{\text{D}} = +77.0$ ($c = 0.96$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 80:20; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_R(S) = 5.12$ min (minor), $t_R(R) = 6.41$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.42 (s, 1H), 7.02 (s, 2H), 6.93 (d, $J = 4.0$ Hz, 2H), 6.11 (s, 1H), 3.49 (s, 3H), 2.39 (s, 3H), 2.38 (s, 3H), 2.29 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.8, 140.1, 139.5, 138.0, 134.8, 131.8, 130.8, 129.3, 124.1, 119.2, 109.4, 69.7, 30.3, 21.3, 20.5, 20.2. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{23}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 295.1805, found: 295.1813.

(R)-[1,1'-biphenyl]-4-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2p)

White solid, 90% yield, 154.0 mg, mp 204-205 °C, $[\alpha]^{25}_{\text{D}} = +35.6$ ($c = 0.56$, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_R(S) = 11.24$ min (minor), $t_R(R) = 13.73$ min (major). ^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, $J = 7.6$ Hz, 2H), 7.55 (d, $J = 8.0$ Hz, 2H), 7.48-7.43 (m, 5H), 7.38 (t, $J = 7.6$ Hz, 1H), 6.97 (s, 1H), 6.24 (s, 1H), 3.54 (s, 3H), 2.38 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.5, 140.5, 139.3, 132.0, 131.0, 128.8, 127.3, 127.2, 127.1, 126.9, 119.2, 109.5, 69.5, 30.3, 20.5, 20.2. HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O} [\text{M}+\text{H}]^+$: 343.1805, found: 343.1812.

(R)-pyridin-4-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2q)

White solid, 85% yield, 113.5 mg, mp 212-213 °C, $[\alpha]^{25}_{\text{D}} = +43.7$ (c = 0.3, MeOH). The *ee* was determined by HPLC on Chiraldak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 13.74$ min (minor), $t_{\text{R}}(R) = 18.43$ min (major). ^1H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 6.4 Hz, 2H), 7.38 (s, 1H), 7.33 (t, *J* = 4.4 Hz, 2H), 6.96 (s, 1H), 6.16 (s, 1H), 3.53 (s, 3H), 2.38 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (100 MHz, CDCl₃) δ 152.9, 149.8, 149.1, 134.5, 132.8, 131.7, 124.0, 120.9, 118.7, 109.7, 68.3, 30.4, 20.5, 20.2. HRMS (ESI) calcd for C₁₆H₁₈N₃O [M+H]⁺: 268.1444, found: 268.1450.

(R)-pyridin-3-yl(1,5,6-trimethyl-1*H*-benzo[d]imidazol-2-yl)methanol (2r)

White solid, 73% yield, 97.5 mg, mp 193-194 °C, $[\alpha]^{25}_{\text{D}} = +35.6$ (c = 0.5, MeOH). The *ee* was determined by HPLC on Chiraldak AD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 20.00$ min (minor), $t_{\text{R}}(R) = 25.78$ min (major). ^1H NMR (400 MHz, DMSO-*d*₆) δ 8.65 (s, 1H), 8.53 (d, *J* = 4.0 Hz, 1H), 7.84 (d, *J* = 8.0 Hz, 1H), 7.42 (d, *J* = 2.8 Hz, 1H), 7.38 (s, 1H), 7.32 (s, 1H), 6.63 (d, *J* = 5.2 Hz, 1H), 6.18 (d, *J* = 5.2 Hz, 1H), 3.77 (s, 3H), 2.36 (s, 3H), 2.31 (s, 3H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 154.1, 148.9, 148.5, 140.6, 137.5, 135.2, 134.8, 131.4, 130.2, 123.7, 119.6, 110.5, 67.1, 30.5, 20.6, 20.3. HRMS (ESI) calcd for C₁₆H₁₈N₃O [M+H]⁺: 268.1444, found: 268.1453.

(R)-1-(1,5,6-trimethyl-1*H*-benzo[d]imidazol-2-yl)ethan-1-ol (2s):

White solid, 99% yield, 204.0 mg, mp 197-198 °C, $[\alpha]^{25}_{\text{D}} = +87.8$ (c = 0.61, MeOH). The *ee* was determined by HPLC on Chiraldak AD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(S) = 10.96$ min (minor), $t_{\text{R}}(R) = 13.18$ min (major). ^1H NMR (400 MHz, CDCl₃) δ 7.43 (s, 1H), 6.96 (d, *J* = 2.8 Hz, 1H), 5.14-5.10 (m, 1H), 4.61 (br, 1H), 3.75 (d, *J* = 1.2 Hz, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 1.69 (d, *J* = 6.4 Hz, 3H). ^{13}C NMR (100 MHz, CDCl₃) δ 155.6, 139.6, 134.5, 131.8, 130.8, 119.2, 109.4, 63.4, 30.0, 22.0, 20.5, 20.2. HRMS (ESI) calcd for C₁₈H₂₁N₂O₂ [M+H]⁺: 205.1335, found: 205.1341.

(R)-1-(1,5,6-trimethyl-1*H*-benzo[d]imidazol-2-yl)propan-1-ol (2t):

White solid, 99% yield, 218 mg, mp 191-192 °C, $[\alpha]^{25}_{\text{D}} = +52.2$ (c = 0.37, MeOH). The *ee* was determined by HPLC on Chiraldak IC-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; $t_{\text{R}}(R) = 11.27$ min (major), $t_{\text{R}}(S) = 12.78$ min (minor). ^1H NMR (600 MHz, CDCl₃) δ 7.39 (s, 1H), 6.92 (s, 1H), 4.81 (t, *J* = 6.6 Hz, 1H), 3.70 (s, 3H), 2.37 (s, 3H), 3.35 (s, 3H), 1.99 (t, *J* = 7.2 Hz, 2H), 0.98 (t, *J* = 7.8 Hz, 3H). ^{13}C NMR (150 MHz, CDCl₃) δ 155.1, 139.9, 134.5, 131.6,

130.7, 119.2, 109.4, 68.9, 30.0, 29.1, 20.5, 20.2, 10.1. HRMS (ESI) calcd for C₁₃H₁₉N₂O [M+H]⁺: 219.1492, found: 219.1499.

(R)-2-phenyl-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)ethan-1-ol (2u):

White solid, 99% yield, 280 mg, mp 195-196 °C, $[\alpha]^{25}_D = +62.8$ (c = 0.25, MeOH). The *ee* was determined by HPLC on Chiralpak IC-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; t_R(R) = 12.73 min (major), t_R(S) = 16.13 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.44 (s, 1H), 7.23 (d, J = 3.6 Hz, 3H), 7.13 (t, J = 4.0 Hz, 2H), 6.93 (s, 1H), 5.60 (br, 1H), 5.14 (t, J = 7.2 Hz, 1H), 3.44-3.33 (m, 5H), 2.40 (s, 3H), 2.38m (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 154.9, 139.9, 137.4, 134.1, 131.7, 130.9, 129.5, 128.4, 126.5, 119.2, 109.5, 68.4, 43.4, 29.6, 20.6, 20.2. HRMS (ESI) calcd for C₁₈H₂₁N₂O₂ [M+H]⁺: 281.1648, found: 281.1652.

(R)-2-methyl-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)propan-1-ol (2v):

White solid, 99% yield, 232 mg, mp 199-201 °C, $[\alpha]^{25}_D = +64.7$ (c = 0.56, MeOH). The *ee* was determined by HPLC on Chiralpak IC-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; t_R(R) = 7.00 min (major), t_R(S) = 9.46 min (minor). ¹H NMR (600 MHz, CDCl₃) δ 7.44 (s, 1H), 7.23 (d, J = 3.6 Hz, 3H), 7.13 (t, J = 4.0 Hz, 2H), 6.93 (s, 1H), 5.60 (br, 1H), 5.14 (t, J = 7.2 Hz, 1H), 3.44-3.33 (m, 5H), 2.40 (s, 3H), 2.38m (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 155.0, 139.8, 134.5, 131.7, 131.0, 119.3, 109.5, 72.8, 30.2, 29.7, 20.5, 20.2, 19.1, 18.0. HRMS (ESI) calcd for C₁₄H₂₁N₂O [M+H]⁺: 233.1648, found: 233.1652.

(S)-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (3a)


White solid, 98% yield, 130.4 mg, mp 207-208 °C, $[\alpha]^{25}_D = -105.1$ (c = 0.74, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; t_R(S) = 7.53 min (major), t_R(R) = 10.72 min (minor). ¹H NMR (400 MHz, CDCl₃) δ 7.41 (s, 1H), 7.36 (d, J = 6.8 Hz, 2H), 7.32-7.27 (m, 2H), 7.25 (d, J = 6.8 Hz, 1H), 6.91 (s, 1H), 6.10 (s, 1H), 3.43 (s, 3H), 2.35 (s, 3H), 2.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 154.5, 140.2, 139.7, 134.9, 131.9, 130.9, 128.5, 127.7, 126.5, 119.3, 109.4, 69.8, 30.1, 20.5, 20.1. HRMS (ESI) calcd for C₁₈H₂₁N₂O₂ [M+H]⁺: 281.1648, found: 281.1655.

(S)-(1-methyl-1*H*-imidazol-2-yl)(phenyl)methanol (3h)


White solid, 84% yield, 79.0 mg, mp 144-145 °C, $[\alpha]^{25}_D = -68.0$ (c = 0.43, MeOH). The *ee* was determined by HPLC on Chiralpak OD-H column, hexane: isopropanol = 90:10; flow rate = 1.0 mL/min; UV detection at 254 nm; t_R(S) = 8.60 min (major), t_R(R) = 14.99 min (minor). ¹H NMR (400 MHz, DMSO-d₆) δ 7.35 (d, J = 4.0 Hz, 4H), 7.27 (d, J = 4.0 Hz, 1H), 7.06 (s, 1H), 6.80 (m, 1H), 6.22 (s, 1H),

5.90 (s, 1H), 3.40 (s, 3H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 149.1, 142.6, 128.4, 127.3, 126.5, 122.8, 68.7, 33.2. HRMS (ESI) calcd for C₁₁H₁₃N₂O [M+H]⁺: 189.1022, found: 189.1031.

IV. Gram scale reaction



Under argon atmosphere, [Ir(COD)Cl]₂ (2.6 mg, 0.003 mmol), **L5** (4.7 mg, 0.0066 mmol), and anhydrous *i*PrOH (4 mL) were added to an oven-dried vial (25 mL) and then stirred at 30 °C for 1.5 h to give a clear yellow solution. The mixture was concentrated to dryness, and then **1a** (6 mmol), HCO₂Na (20.4 mg, 0.3 mmol) and anhydrous Toluene (10 mL) were added. The vial was placed in an alloy plate which was then placed into the autoclave. And the autoclave was purged five times with hydrogen, then pressurized to 50 atm of H₂ and stirred at 70 °C for 24 h. Upon completion, the reaction mixture was cooled to room temperature. After the hydrogen pressure was slowly released, the solvent was removed, and the mixture was purified by passing through a short column of silica gel to afford **2a** in 1.55g, 97% yield with 96% *ee*. The *ee* values of all compounds were determined by HPLC with a chiral column.




V. References


- (1) F. Ling, S. Nian, J. Chen, W. Luo, Z. Wang, Y. Lv and W. Zhong, *J. Org. Chem.*, 2018, **83**, 10749-10761.
- (2) S. Nian, F. Ling, J. Chen, Z. Wang, H. Shen, X. Yi, Y. F. Yang, Y. She and W. Zhong, *Org. Lett.*, 2019, **21**, 5392-5396.
- (3) S. B. Kadin, H. J. Eggers and I. Tamm, *Nature*, 1964, **201**, 639-640.
- (4) A. Torrens, J. A. Castrillo, A. Claparols and J. Redondo, *Synlett*, 1999, **6**, 765-767.

VI. Copies of ^1H and ^{13}C NMR spectra


*N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L1)*




^1H NMR - 400 MHz, CDCl_3




^{13}C NMR - 100 MHz, CDCl_3







³¹P NMR - 162 MHz, CDCl₃





N-((1*S*,2*S*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L2)




¹H NMR - 400 MHz, CDCl₃








N-((1*R*,2*R*)-2-(((*S*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L3)




¹H NMR - 400 MHz, CDCl₃





¹³C NMR - 100 MHz, CDCl₃







N-((1*S*,2*S*)-2-(((*S*)-1-(2-(diphenylphosphoryl)ferrocenyl)ethyl)amino)cyclohexyl)-4-methylbenzenesulfonamide (L4)








N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L5)










N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-triisopropylbenzenesulfonamide (L6)






N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-3,5-bis(trifluoromethyl)benzenesulfonamide (L7)






***N*-((1*R*,2*R*)-2-(((*R*)-1-(2-(bis(3,5-dimethylphenyl)phosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L8)**




1H NMR - 400 MHz, CDCl₃





141.392
140.916
140.804
138.982
138.385
137.812
137.429
135.511
135.298
134.621
132.554
132.374
131.322
129.119
128.517
128.326
128.141
128.088
128.011
127.603
127.463
127.216
126.870
98.644

77.377
77.059
76.742
74.028
73.935
71.362
69.960
69.722
69.547
65.036
63.390
-47.464






13C NMR - 100 MHz, CDCl₃







*N-((1*R*,2*R*)-2-(((*R*)-1-(2-(dicyclohexylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L9)*










N-((1*R*,2*R*)-2-(((*R*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)-1,2-diphenylethyl)-2,4,6-trimethylbenzenesulfonamide (L10)








(R)-3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-((1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclobut-3-ene-1,2-dione (L11)




¹H NMR - 400 MHz, CDCl₃






¹³C NMR - 100 MHz, CDCl₃







N-((1*S*,2*S*)-2-(((*S*)-1-(2-(diphenylphosphanyl)ferrocenyl)ethyl)amino)cyclohexyl)-2,4,6-trimethylbenzenesulfonamide (L12)







(R)-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2a)





(R)-(5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2b)




(R)-(1-benzyl-5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2c)





(R)-(5,6-dimethyl-1-phenyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2d)




¹³C NMR - 100 MHz, CDCl₃





(R)-(1-isopropyl-5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2e)




(R)-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2f)




(R)-(5,6-difluoro-1-methyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2g)




13C NMR - 100 MHz, DMSO-d6





(R)-(1-methyl-1*H*-imidazol-2-yl)(phenyl)methanol (2h)




¹³C NMR - 100 MHz, CDCl₃





(R)-*p*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2i)




1H NMR - 400 MHz, CDCl₃





(R)-(4-fluorophenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2j)





13C NMR - 100 MHz, CDCl₃




(R)-(4-chlorophenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2k)




(R)-(4-(trifluoromethyl)phenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2l)




1H NMR - 600 MHz, CDCl₃




(R)-[1,1'-biphenyl]-4-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2m)




1H NMR - 400 MHz, CDCl₃





13C NMR - 100 MHz, CDCl₃





(R)-*m*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2n)





(R)-*o*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2o)



(R)-(3,5-dimethylphenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2p)




(R)-pyridin-4-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2q)




(R)-pyridin-3-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2r)




1H NMR - 400 MHz, DMSO-d6





13C NMR - 100 MHz, DMSO-d6





(R)-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)ethan-1-ol (2s)




(R)-1-(1,5,6-trimethyl-1*H*-benzo[d]imidazol-2-yl)propan-1-ol (2t)



(R)-2-phenyl-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)ethan-1-ol (2u)




13C NMR - 100 MHz, CDCl₃




(*R*)-2-methyl-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)propan-1-ol (2v)




1.077
1.066
0.913
0.902




¹H NMR - 600 MHz, CDCl₃






30.190
29.710
20.536
20.213
19.137
18.025




¹³C NMR - 150 MHz, CDCl₃




(S)-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (3a)



(S)-(1-methyl-1*H*-imidazol-2-yl)(phenyl)methanol (3h)




13C NMR - 100 MHz, CDCl₃




VII. Copies of HPLC charts of chiral alcohols 2a-2v, 3a, 3h


(R)-phenyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2a)




(R)-(5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2b)




(R)-(1-benzyl-5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2c)




(R)-(5,6-dimethyl-1-phenyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2d)




(R)-(1-isopropyl-5,6-dimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2e)




(R)-(1-methyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2f)




(R)-(5,6-difluoro-1-methyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (2g)




(R)-(1-methyl-1*H*-imidazol-2-yl)(phenyl)methanol (2h)




(R)-*p*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2i)




(R)-(4-fluorophenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2j)




(R)-(4-chlorophenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2k)




(R)-(4-(trifluoromethyl)phenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2l)




(R)-*m*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2m)




(R)-*o*-tolyl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2n)




(R)-(3,5-dimethylphenyl)(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2o)




(R)-[1,1'-biphenyl]-4-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2p)




(R)-pyridin-4-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2q)




(R)-pyridin-3-yl(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)methanol (2r)




(R)-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)ethan-1-ol (2s)




(R)-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)propan-1-ol (2t)



(R)-2-phenyl-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)ethan-1-ol (2u)




(R)-2-phenyl-1-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)ethan-1-ol (2v)



Processed Channel Descr.: W2489 ChA 254nm



Processed Channel Descr.	RT	Area	% Area	Height
1 W2489 ChA 254nm	6.979	9614130	50.56	768682
2 W2489 ChA 254nm	9.327	9399472	49.44	532324



Processed Channel Descr.: W2489 ChA 254nm

Processed Channel Descr.	RT	Area	% Area	Height
1 W2489 ChA 254nm	6.996	25568569	96.12	1880402
2 W2489 ChA 254nm	9.463	1033075	3.88	60072

(S)-(1,5,6-trimethyl-1*H*-benzo[*d*]imidazol-2-yl)(phenyl)methanol (3a)



(S)-(1-methyl-1*H*-imidazol-2-yl)(phenyl)methanol (3h)

